会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明申请
    • Methods for predicting survival in metastatic melanoma patients
    • 预测转移性黑色素瘤患者生存的方法
    • US20110275089A1
    • 2011-11-10
    • US12932068
    • 2011-02-17
    • Dusan BogunovicNina BhardwajDavid O'Neill
    • Dusan BogunovicNina BhardwajDavid O'Neill
    • C12Q1/68C12Q1/06
    • C12Q1/6886C12Q2600/106C12Q2600/118C12Q2600/158G01N33/5743G01N2800/52
    • Cellular and genetic signatures and methods of using same for subcategorizing stage III melanoma tumors are described herein. The signatures and methods are particularly useful with regard to establishing more distinct criteria on which basis to differentiate stage IIIB and IIIC melanoma patients. Assessment of the cellular and genetic signatures of a melanoma sample using methods described herein yields information on which basis differential survival duration and sensitivity to various cancer therapies can be predicted for a Stage IIIB or Stage IIIC melanoma patients. As described herein, gene expression profiling, determination of mitotic index (MI), and quantification of tumor infiltrating leukocytes (TILs) and CD3+ cells in metastatic lesions may be utilized to predict or assess drug response, drug sensitivity, and clinical outcome in metastatic melanoma patients.
    • 本文描述了细胞和遗传标记以及将其用于次级分类III期黑素瘤肿瘤的方法。 签署和方法对于建立更明确的标准来区分IIIB期和IIIC期黑素瘤患者是特别有用的。 使用本文所述的方法评估黑素瘤样品的细胞和遗传标记产生关于IIIB期或IIIC期黑素瘤患者可以预测基础差异存活期和对各种癌症疗法的敏感性的信息。 如本文所述,转移性病变中的基因表达谱,有丝分裂指数(MI)的测定和肿瘤浸润性白细胞(TIL)和CD3 +细胞的定量可用于预测或评估转移性黑素瘤中的药物反应,药物敏感性和临床结果 耐心。